Newton Biocapital operates as a Belgium-Japan biotech fund with offices in Brussels and Tokyo, founded by Alain Parthoens and Goro Takeda and later joined by Japan-based leaders Tomoko Asaoka and Sadashi Suzuki; it became the first European venture capital fund certified by Japan's Agency for Medical Research and Development and one of the first foreign funds admitted to a Health Ministry-supported translational drug discovery program, while also using its first fund to help create four academic spin-offs and one spin-out. The fund sources Japanese platform companies like PRISM BioLab, EditForce, J-Pharma, and Perseus Proteomics for European capital and networks, and its first fund built investor syndicates where every euro it invested was matched by a multiple from other investors.